NCT03480932View on ClinicalTrials.gov

Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

November 2, 2018

Study Completion Date

November 2, 2018

Conditions

Hepatitis C, Chronic

Interventions

DRUG

Sofosbuvir

Direct acting antiviral agent used for the treatment of hepatitis C

DRUG

Daclatasvir

Direct acting antiviral agent used for the treatment of hepatitis C

DRUG

Pegylated Interferon alfa-2a

Antiviral agent used for the treatment of hepatitis C

Trial Locations (1)

495009

YR Gaitonde Centre for AIDS Education and Johns Hopkins University Collaborative Integrated Care Center (YRG-JHU ICC), Bilāspur

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

YR Gaitonde Centre for AIDS Research and Education

OTHER

lead

Johns Hopkins Bloomberg School of Public Health

OTHER

NCT03480932 - Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] | Biotech Hunter | Biotech Hunter